For much of the twentieth century, mammalian development was viewed primarily as a one-way journey. In the classic image proposed by developmental biologist Conrad Waddington in 1957, a ball rolls down a mountainous landscape, leaving the high plateau of developmental potential and settling into increasingly specialized valleys. Embryonic stem cells could differentiate into restricted lineages, but a mature cell was thought to have largely lost the ability to climb back up the landscape. That model captured the stability of cell identity, but it did not fully describe its potential reversibility. The conceptual breakthrough came in 2006, when Shinya Yamanaka and colleagues reported that four transcription factors could convert mouse fibroblasts into cells with properties resembling embryonic stem cells.

The factors—Oct3/4, Sox2, Klf4, and c-Myc, commonly abbreviated as OSKM—act as molecular regulators of gene expression rather than as structural components of the cell. When introduced into differentiated fibroblasts, they reorganize the gene-regulatory circuitry that maintains the mature state. They also reshape chromatin, the DNA-protein material that determines which genes are accessible for transcription. Over time, genes associated with fibroblast identity are silenced while networks linked to self-renewal and pluripotency become active. The process is inefficient and asynchronous: only a small fraction of treated cells successfully complete the transition, and individual cells may pass through different intermediate states before reaching an induced pluripotent state.

This inefficiency revealed that reprogramming is not a simple molecular reset controlled by four independent switches. Instead, it is a competition between stable cellular programs, epigenetic barriers, metabolic changes, and stochastic events. Some cells fail to activate the core pluripotency network, while others enter incomplete or abnormal states. DNA methylation patterns must be extensively remodeled, enhancer activity must be reorganized, and the cell’s metabolism must shift as it moves from a mature somatic program toward a stem-cell-like condition. These changes helped establish a broader principle: differentiation and reprogramming are opposing movements across a dynamic developmental landscape. Understanding how a cell enters, maintains, or exits pluripotency can therefore illuminate both normal development and the mechanisms used to reverse it.

The underlying idea that differentiated cells retain latent developmental potential was demonstrated decades earlier by John Gurdon. In experiments published in 1962, Gurdon transferred the nucleus of a differentiated tadpole intestinal cell into an enucleated frog egg. The reconstructed embryo could develop into a normal tadpole, showing that the specialized nucleus still contained the genetic information required to build an organism. Nuclear transfer, however, depended on the complex environment of an egg cell. Yamanaka’s work was transformative because it showed that mammalian cell identity could be altered using a small set of defined transcription factors alone. The discovery converted a question once associated with embryology into a practical technology that could be reproduced in laboratories around the world.

The next year, researchers generated induced pluripotent stem cells from adult human fibroblasts. Human iPSCs gave scientists a way to create genetically relevant, patient-specific cell lines without relying on embryos. In principle, a skin or blood sample can be reprogrammed and then differentiated into neurons, heart muscle cells, liver cells, retinal cells, or other specialized populations. These cells can carry disease-associated genetic variants, allowing researchers to study pathological mechanisms in a dish. They can also be used to test candidate medicines on human-derived tissue, potentially revealing toxicities or treatment responses that conventional animal models do not predict reliably. Yet the technology carries important technical challenges, including genomic instability, residual epigenetic memory, variation between cell lines, incomplete differentiation, and the risk that undifferentiated cells could form tumors after transplantation.

The clinical ambitions of the field are now moving beyond theory. Early-stage trials have tested cell products derived from pluripotent stem cells, including retinal pigment epithelium intended to treat macular degeneration and dopaminergic neurons designed to replace cells lost in Parkinson’s disease. The goal is not simply to place stem cells into damaged tissue, but to manufacture a highly characterized population with the correct identity, maturity, function, and safety profile. Researchers must establish that the cells do not contain dangerous mutations, that unwanted cell types have been removed, and that the transplanted population behaves predictably over time. Manufacturing at clinical scale also requires tightly controlled culture conditions, standardized quality testing, and long-term monitoring of patients.

The field is simultaneously expanding in directions that challenge the original definition of reprogramming. Partial reprogramming, for example, exposes cells to reprogramming factors for a limited period rather than pushing them all the way to pluripotency. In experimental systems, this approach has been used to reverse some molecular features associated with aging while preserving aspects of the cell’s original identity. The strategy is technically delicate: too little reprogramming may produce minimal benefit, while too much can erase cell identity or promote abnormal growth. Chemical reprogramming offers another alternative. Instead of delivering transcription-factor genes, researchers use combinations of small molecules to alter signaling pathways, chromatin states, metabolism, and transcriptional regulation. This may improve control over timing and reduce some risks associated with genetic delivery, although efficiency, reproducibility, and safety remain major obstacles.

New measurement technologies are making these transitions visible at unprecedented resolution. Single-cell RNA sequencing can track gene-expression changes in individual cells rather than averaging signals across an entire culture. Single-cell epigenomic methods reveal how DNA methylation, histone modifications, and chromatin accessibility change during fate conversion. Spatial transcriptomics adds a geographic dimension, showing where distinct cell states occur within tissues or organoid structures. Advanced imaging can follow cell division, morphology, and lineage behavior in real time, while computational models reconstruct gene-regulatory networks and identify the molecular events that separate successful reprogramming from failure. Together, these approaches are transforming cellular identity from a static label into a measurable trajectory through molecular and physical states.

Another rapidly developing frontier is the construction of stem-cell-based embryo and tissue models. Organoids can reproduce selected features of organs, including aspects of tissue architecture, physiology, and disease. More integrated models attempt to recreate interactions among multiple lineages during early development, offering a way to investigate processes that are difficult or impossible to observe directly in embryos. These systems can reveal how signaling pathways, mechanical forces, cell migration, chromatin organization, and metabolism cooperate to produce organized tissues. They also raise difficult ethical and regulatory questions, particularly as models become more complex and begin to resemble aspects of embryonic development more closely. The anniversary collection announced by BMC Biology is intended to bring together research addressing these biological, technological, and ethical challenges.

Twenty years after OSKM first overturned the idea that development is irreversible, the central question has become more precise: not merely whether a cell can change identity, but how that change is initiated, stabilized, coordinated across a population, and safely directed toward a therapeutic outcome. Scientists are now examining developmental plasticity in diverse species, the spatial organization of lineage decisions, the molecular logic of tissue patterning, and the systems-level principles that integrate gene regulation with signaling, metabolism, and mechanics. The history of iPSCs began with a compact set of transcription factors, but its future will depend on far more than four genes. It will require predictive models of cell fate, reliable methods for producing mature functional cells, and rigorous safeguards that convert cellular plasticity into medicine without sacrificing biological control.

Subject of Research: Induced pluripotent stem cells, cellular reprogramming, pluripotency, differentiation, developmental plasticity, stem-cell-based models, and regenerative medicine

Article Title: Pluripotency, differentiation, and reprogramming: 20 years of induced pluripotent stem cells

Article References: Takahashi and Yamanaka, Cell (2006), DOI: 10.1016/j.cell.2006.07.024; Gurdon, Journal of Embryology and Experimental Morphology (1962); Takahashi et al., Cell (2007), DOI: 10.1016/j.cell.2007.11.019; Yu et al., Science (2007), DOI: 10.1126/science.1151526; Shi et al., Nature Reviews Drug Discovery (2017), DOI: 10.1038/nrd.2016.245; Mandai et al., New England Journal of Medicine (2017), DOI: 10.1056/NEJMoa1608368; Sawamoto et al., Nature (2025), DOI: 10.1038/s41586-025-08700-0; Ocampo et al., Cell (2016), DOI: 10.1016/j.cell.2016.11.052; Guan et al., Nature (2022), DOI: 10.1038/s41586-022-04593-5; Eiraku et al., Nature (2011), DOI: 10.1038/nature09941

Image Credits: AI Generated

DOI: 10.1186/s12915-026-02712-6

Keywords: induced pluripotent stem cells, iPSCs, pluripotency, cellular reprogramming, OSKM, Yamanaka factors, differentiation, stem cell biology, regenerative medicine, organoids, embryo models, single-cell multi-omics, spatial transcriptomics, partial reprogramming, chemical reprogramming

Stem cell treatments have long been viewed as a potential solution for conditions in which the body cannot adequately replace or repair damaged cells. These therapies are being investigated for degenerative disorders, skeletal injuries, neurological diseases, cancer, and age-related tissue decline. Yet stem cells must be carefully controlled. They need to retain their ability to self-renew without becoming abnormal, while also responding precisely to signals that direct them toward specific cell fates. According to the review, PIWI proteins and piRNAs may help coordinate this delicate balance by controlling gene activity at several levels.

PiRNAs are short RNA molecules that typically range from approximately 24 to 32 nucleotides in length. Unlike messenger RNA, which carries instructions for producing proteins, piRNAs act primarily as regulatory molecules. They bind to PIWI proteins, a specialized subgroup of the Argonaute protein family, to form molecular complexes capable of recognizing and silencing particular genetic sequences. One of their best-known functions is the suppression of transposable elements, sometimes called “jumping genes,” which can move around the genome and cause mutations or disrupt gene regulation.

This genome-protection mechanism is especially important in cells that must preserve their genetic integrity over long periods. When transposable elements become active, they can insert themselves into new locations in DNA, interfere with genes, and generate chromosomal instability. PIWI/piRNA complexes can suppress these elements by cutting their RNA transcripts and by encouraging the formation of repressive chromatin around their DNA sequences. Through this process, the pathway helps keep potentially damaging genetic elements inactive while maintaining the stable cellular environment required for stem cell function.

The review highlights that PIWI/piRNA activity extends beyond the direct destruction of transposon RNA. These complexes can influence epigenetic regulation, a system of molecular controls that changes gene activity without altering the DNA sequence itself. PIWI proteins and piRNAs have been linked to DNA methylation, histone modification, and chromatin remodeling. By altering how tightly DNA is packaged, they can affect whether particular genes are accessible to the cellular machinery responsible for transcription. Such regulation may help stem cells remain in an undifferentiated state or activate the gene programs needed for differentiation.

Although the PIWI/piRNA pathway was initially associated primarily with reproductive tissues, researchers have identified related activity in a growing range of somatic cells. The review describes evidence suggesting that these molecules may contribute to tissue maintenance, wound repair, bone formation, nervous system function, and cellular responses to stress. Their presence in non-reproductive tissues has expanded interest in the pathway and raised the possibility that piRNAs could serve as molecular indicators of tissue condition or disease activity.

Cancer research is one of the areas attracting particular attention. Abnormal PIWI or piRNA expression has been observed in several tumor types, where the pathway may influence cancer stem cells, uncontrolled growth, invasion, and resistance to treatment. Cancer stem cells are a small population of tumor cells with the ability to self-renew and generate new cancer cells, making them difficult to eliminate completely. If specific PIWI/piRNA networks help these cells survive chemotherapy or maintain their aggressive properties, disrupting those networks could provide a new therapeutic strategy. However, the precise effects appear to vary according to the cancer type and the individual piRNA involved.

The pathway may also have applications in regenerative medicine. Certain piRNAs appear to regulate the formation and activity of bone-forming cells, suggesting potential uses in treating osteoporosis, bone defects, and impaired skeletal healing. Other studies have connected PIWI/piRNA activity with neural stem cells and processes associated with healthy aging. These findings raise the possibility of using selected piRNAs as biomarkers to monitor stem cell quality, predict treatment responses, or identify early molecular changes associated with disease.

Despite the promise, PIWI/piRNA-based therapies remain at an early stage. Researchers must determine which piRNAs have reliable and beneficial effects, identify their precise molecular targets, and prevent unintended changes in gene regulation. Delivery is another major challenge because RNA molecules can be unstable and may not reach the intended cells in sufficient quantities. Future progress may come from improved gene-delivery systems, engineered nanoparticles, biomaterials, and computational tools that use artificial intelligence to predict interactions between piRNAs and their targets. The review concludes that a clearer understanding of this complex regulatory system could eventually make stem cell therapies safer, more precise, and more effective, while also opening new avenues for cancer treatment and tissue regeneration.

Subject of Research: PIWI proteins and PIWI-interacting RNAs (piRNAs) in stem cell regulation, epigenetic control, cancer biology, and regenerative medicine.

Article Title: Unraveling the role of PIWI/piRNAs in stem cell therapy: Epigenetic mechanisms and therapeutic potentials

Web References: https://doi.org/10.1016/j.gendis.2025.101854

References: Ying Yang, Xiangping Luo, Ermao Li, Zhengmao Li, Feiyan Zou, Jiayang Liao, Yizhi Wu, Bo Wei, “Unraveling the role of PIWI/piRNAs in stem cell therapy: Epigenetic mechanisms and therapeutic potentials,” Genes & Diseases, Volume 13, Issue 5, 2026, Article 101854. DOI: 10.1016/j.gendis.2025.101854

Image Credits: Genes & Diseases

Keywords: stem cell therapy, PIWI proteins, piRNAs, epigenetics, genome stability, transposons, chromatin remodeling, cancer stem cells, bone regeneration, neural stem cells, regenerative medicine, biomarkers